Case: Patents/Procedure (Fed. Cir.)

The Federal Circuit affirmed the decision of a federal district court in West Virginia finding that Mylan Pharmaceuticals Inc.'s proposed generic drug infringes challenged claims of Actelion Pharmaceuticals Ltd.'s patents that describe certain pharmaceutical compositions involving epoprostenol. The appeals court affirmed the district court’s findings of no literal infringement and that Actelion was barred from asserting, and had not proved, infringement by an equivalent.